All News

EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
SLE,malar,black

Damage in Childhood Lupus

EurekAlert!

Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.

Read Article
couple holding hands with baby shoes

RA: update for women of child bearing potential (and men!)

Aurelie Najm, MD, PhD

Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.

EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.

Read Article
pssfing.jpg

New Treatments for Systemic Sclerosis

EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.

Read Article
Convention1.jpg

EULAR 2024 – Day 4 Report

Jack Cush, MD

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article
steroids.prednisone.pills_.jpg

Update on low-dose glucocorticoids in SLE

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an achievable target?

Read Article
LBP_0.jpg

Achieving drug-free remission in axSpA

EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.

Read Article
GCA,woman

Choices in GCA

David Liew, FRACP

There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Read Article
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: update for women of child bearing potential (and men!) Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients. https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions. https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo

Links:

Dr. John Cush RheumNow ( View Tweet)
Impact of regulatory warning on JAK inhibitors JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death. https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 - Day 1 Report https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8

Links:

Dr. John Cush RheumNow ( View Tweet)
PMR patients get too much steroid. Data across 27 million people in England, n=39,438 with PMR. The blue are getting more pred than guidelines. Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help. #EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm

Links:

David Liew drdavidliew ( View Tweet)
EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

placebo effects can be huge! #EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye

Links:

Bella Mehta bella_mehta ( View Tweet)
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

lets put this bed now @RheumNow #EULAR https://t.co/r0SVoOk47O

Links:

Peter Nash drpnash ( View Tweet)
opposing point of view to previous post @RheumNow #EULAR2024 https://t.co/T72r8kXF1j

Links:

Peter Nash drpnash ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×